FDA Approved: VOXZOGO 0.4MG — Supplemental Application (BioMarin Pharmaceutical Inc.)

View source ↗

Summary

FDA approves BioMarin's supplemental application for VOXZOGO 0.4 mg (vosoritide), adding a 0.4 mg dosage strength to the labeling for achondroplasia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Achondroplasia

Drugs mentioned

• VOXZOGO 0.4MG (vosoritide)

Snippet

SUPPL AP for VOXZOGO 0.4MG (VOSORITIDE)